Phaseline

Companies › Amgen

Amgen: clinical trials, targets and expected readouts

32 active drug programs in 277 registered trials: 113 Phase 2, 73 Phase 3, 62 Phase 1, 29 Phase 4; Oncology, Metabolic and endocrine, Other, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Denosumab
Tumor necrosis factor ligand superfamily member 11 inhibitor
TNFSF11Phase 4Osteoporosis; Glucocorticoid-induced Osteoporosis; Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal …Jan 2027
Inebilizumab
B-lymphocyte antigen CD19 binding agent
CD19Phase 4Neuromyelitis Optica Spectrum Disorder; IgG4 Related Disease; Myasthenia Gravis; Autoimmune Hepatitis …Apr 2027
Evolocumab
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 4Cardiovascular DiseaseMay 2027
Avacopan
C5a anaphylatoxin chemotactic receptor antagonist
C5AR1Phase 4Antineutrophil Cytoplasmic Antibody-associated Vasculitis; Vasculitis; ANCA Associated Vasculitis (AAV); Granulomatosis With PolyangiitisJul 2027
Maridebart cafraglutide (AMG 133)
GLP-1 receptor agonist and GIP receptor agonist (dual GLP-1/GIP receptor agonist)
GLP1R, GIPRPhase 3Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight; Obesity; Obesity Disease; Obstructive Sleep Apnea …Nov 2026
Teprotumumab
Insulin-like growth factor I receptor antagonist
IGF1RPhase 3Thyroid Eye DiseaseNov 2026
Erenumab
Calcitonin gene-related peptide type 1 receptor antagonist
CALCRLPhase 3Migraine; Posttraumatic Headache; SchwannomatosisNov 2026
ABP 234
PD-1 inhibitor (pembrolizumab biosimilar)
PDCD1Phase 3Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC); Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerDec 2026
Dazodalibep
CD40 ligand antagonist
CD40LGPhase 3Sjögren's Syndrome (SS); Sjögren's Syndrome; Lupus NephritisDec 2026
Sotorasib
GTPase KRas inhibitor
KRASPhase 3Non-Small Cell Lung Cancer (NSCLC); Metastatic Colorectal Cancer; Advanced Solid Tumors; Lung Adenocarcinoma …Dec 2026
Romosozumab
Sclerostin inhibitor
SOSTPhase 3Osteogenesis Imperfecta; Healthy Participants; Osteoporosis; Postmenopausal Osteoporosis …Jan 2027
Xaluritamig (AMG 509)–Phase 3Metastatic Castration-resistant Prostate Cancer; Prostate Cancer; Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Ewing Sarcoma …Feb 2027
Romiplostim
Thrombopoietin receptor agonist
MPLPhase 3Chemotherapy-induced Thrombocytopenia; Primary Immune Thrombocytopenia; CTIT: Cancer Therapy Induced Thrombocytopenia; Solid Tumors …Feb 2027
ABP 692
Anti-CD20 monoclonal antibody
MS4A1Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)Apr 2027
Tarlatamab
T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent
CD3E, CD3G, CD3D, DLL3Phase 3Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Small-cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer …Apr 2027
Etelcalcetide
Calcium sensing receptor agonist
CASRPhase 3Secondary HyperparathyroidismJun 2027
ABP 938
Anti-VEGF monoclonal antibody
VEGFAPhase 3Neovascular Age-related Macular DegenerationJul 2027
Blinatumomab
T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent
CD3E, CD3G, CD3D, CD19Phase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL); B Precursor Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus; B Cell Precursor Acute Lymphoblastic Leukemia …Oct 2027
ABP 206
PD-L1 inhibitor
CD274Phase 3MelanomaJan 2028
Apremilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 3Plaque Psoriasis; Active Juvenile Psoriatic Arthritis; Behçet Disease; Behçet's Disease …Mar 2028
Olpasiran
LPA mRNA rnai inhibitor
LPAPhase 3Atherosclerotic Cardiovascular Disease; Cardiovascular DiseaseMar 2028
Pegloticase
Recombinant uricase enzyme that catalyzes degradation of uric acid
PTENPhase 3Uncontrolled GoutJun 2028
Panitumumab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Metastatic Colorectal Cancer; Advanced Solid Tumors; Colorectal Cancer Stage IV; Colorectal Neoplasms …Jul 2028
anvumetostat
PRMT5 inhibitor in MTAP-deleted tumors
PRMT5Phase 2MTAP-deleted NSCLC; Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers; Advanced MTAP-null Solid Tumors; Thoracic TumorsNov 2026
AMG 732
Insulin Growth Factor-1 Receptor (IGF-1R) pathway inhibitor via IGSF8 binding
IGSF8Phase 2Thyroid Eye DiseaseJan 2027
RMC-4630
KRAS inhibitor (CoA-alkynes)
–Phase 1Advanced Solid TumorsDec 2026
GnRH Antagonist
Gonadotropin-releasing hormone antagonist
GNRHRPhase 1Prostate Cancer; Atypical Endometrial Hyperplasia; Endometrial NeoplasmsFeb 2027
AMG 691
Unclear mechanism
–Phase 1Healthy Participants; AsthmaMar 2027
AMG 127–Phase 1Diabetes Mellitus, Type 2Oct 2027
AMG 509
PSCA-directed chimeric costimulatory receptor T cell therapy
PSCAPhase 1Extensive Stage Small Cell Lung Cancer; Prostate Cancer; Small Cell Lung CancerMar 2028
AMG 410
KRAS G12C inhibitor
KRASPhase 1KRAS Altered Advanced or Metastatic Solid TumorsApr 2028
AMG 436–Phase 1Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)Jan 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03623633DenosumabPhase 4Osteoporosis, PostmenopausalMetabolic and endocrineFeb 2023
NCT05212337DenosumabPhase 2Infertility, MaleGenitourinaryOct 2024
NCT04549207DenosumabPhase 4Breast CancerOncologyApr 2025
NCT02790515BlinatumomabPhase 2Acute Lymphoblastic Leukemia (ALL)OncologyJul 2025
NCT06509984ApremilastPhase 2Epidermolysis Bullosa SimplexOtherOct 2025
NCT03512405BlinatumomabPhase 1CD19 PositiveOncologyNov 2025
NCT05565560ApremilastPhase 3Plaque PsoriasisImmunologyNov 2025
NCT05096195DenosumabPhase 4Kidney DiseasesGenitourinaryDec 2025
NCT06759636RomiplostimPhase 3CTIT: Cancer Therapy Induced ThrombocytopeniaOncologyApr 2026
NCT05182385BlinatumomabPhase 1ALL, Recurrent, AdultOncologyApr 2026
NCT07283887RomosozumabPhase 4OsteoporosisMetabolic and endocrineJul 2026
NCT07063225RomiplostimPhase 2Chemotherapy-induced ThrombocytopeniaHematologyAug 2026
NCT06324435ApremilastPhase 1Alcohol Use DisorderPsychiatryAug 2026
NCT07043894RomiplostimPhase 2Solid TumorsOncologySep 2026
NCT05325593RomiplostimPhase 3Primary Immune ThrombocytopeniaHematologyOct 2026
NCT02877303BlinatumomabPhase 2B Acute Lymphoblastic LeukemiaOncologyNov 2026
NCT06660173Maridebart cafraglutide (AMG 133)Phase 2Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineNov 2026
NCT06248619TeprotumumabPhase 3Thyroid Eye DiseaseOphthalmologyNov 2026
NCT07160257Maridebart cafraglutide (AMG 133)Phase 1Type 2 Diabetes MellitusMetabolic and endocrineNov 2026
NCT03836040ErenumabPhase 3MigraineNeurologyNov 2026
NCT07523711Maridebart cafraglutide (AMG 133)Phase 1OverweightMetabolic and endocrineNov 2026
NCT03755193DenosumabPhase 2OsteoporosisMetabolic and endocrineNov 2026
NCT06249282SotorasibPhase 1Advanced Lung Non-Small Cell CarcinomaOncologyNov 2026
NCT06593522anvumetostatPhase 2MTAP-deleted NSCLCOncologyNov 2026
NCT06360354anvumetostatPhase 1Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersGastroenterologyNov 2026
NCT05094336anvumetostatPhase 1Advanced MTAP-null Solid TumorsOncologyNov 2026
NCT06333951anvumetostatPhase 1Thoracic TumorsOncologyNov 2026
NCT06749886DenosumabPhase 2Lung CancerOncologyNov 2026
NCT03983993PanitumumabPhase 2Advanced Microsatellite Stable Colorectal CarcinomaOncologyDec 2026
NCT06387121BlinatumomabPhase 2Precursor Cell Lymphoblastic Leukemia-LymphomaOncologyDec 2026
NCT06693791RomiplostimPhase 2Platelet Recovery After Umbilical Cord Blood TransplantationOtherDec 2026
NCT06430866ABP 234Phase 3Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)OncologyDec 2026
NCT04227314ApremilastPhase 3Recurrent Aphtous StomatitisGastroenterologyDec 2026
NCT03541083BlinatumomabPhase 2ALL, AdultOncologyDec 2026
NCT04185883SotorasibPhase 1Advanced Solid TumorsOncologyDec 2026
NCT06245408DazodalibepPhase 3Sjögren's Syndrome (SS)ImmunologyDec 2026
NCT04185883RMC-4630Phase 1Advanced Solid TumorsOncologyDec 2026
NCT03114865BlinatumomabPhase 1Acute Lymphoblastic LeukemiaOncologyDec 2026
NCT04625647SotorasibPhase 2Lung AdenocarcinomaOncologyDec 2026
NCT06339775BlinatumomabPhase 4Acute B-cell Lymphoblastic LeukemiaOncologyDec 2026
NCT06250959BlinatumomabPhase 2ALL, AdultOncologyDec 2026
NCT06401044AMG 732Phase 1Thyroid Eye DiseaseOphthalmologyJan 2027
NCT07811999RomosozumabPhase 1Healthy ParticipantsOtherJan 2027
NCT06886074BlinatumomabPhase 2Acute Lymphoblastic LeukemiaOncologyJan 2027
NCT06858878Maridebart cafraglutide (AMG 133)Phase 3Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightMetabolic and endocrineJan 2027
NCT06858839Maridebart cafraglutide (AMG 133)Phase 3ObesityMetabolic and endocrineJan 2027
NCT06332014DenosumabPhase 4OsteoporosisMetabolic and endocrineJan 2027
NCT03087071PanitumumabPhase 2EGFR NP_005219.2:p.S492ROncologyJan 2027
NCT07325266ApremilastPhase 2Alcohol Use DisorderPsychiatryJan 2027
NCT06898983RomiplostimPhase 2Cancer Treatment-induced Thrombocytopenia (CTIT)OncologyJan 2027
NCT03739814BlinatumomabPhase 2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeOncologyFeb 2027
NCT05519579BlinatumomabPhase 2Acute Lymphoblastic LeukemiaOncologyFeb 2027
NCT07854561RomiplostimPhase 2Anemia Associated With Chronic Kidney DiseaseGenitourinaryFeb 2027
NCT06613100Xaluritamig (AMG 509)Phase 1Prostate CancerOncologyFeb 2027
NCT06613100GnRH AntagonistPhase 1Prostate CancerOncologyFeb 2027
NCT03937154RomiplostimPhase 3Chemotherapy-induced ThrombocytopeniaOncologyFeb 2027
NCT02003222BlinatumomabPhase 3Acute Lymphoblastic LeukemiaOncologyFeb 2027
NCT05747625PanitumumabPhase 1Head and Neck Squamous Cell CarcinomaOncologyFeb 2027
NCT03147612BlinatumomabPhase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveOncologyFeb 2027
NCT04608630DenosumabPhase 2Critical IllnessMetabolic and endocrineFeb 2027

The 60 nearest readouts of 277 trials; the rest in the app.

From the company's SEC filings

Cash of $13.2bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Targets

CD3E (2) CD3G (2) CD3D (2) KRAS (2) CD19 (2) GLP1R (1) GIPR (1) DLL3 (1) CASR (1) EGFR (1) C5AR1 (1) PDE4A (1)

Companies with the same targets

Roche Johnson & Johnson (Janssen) Eli Lilly Bristol-Myers Squibb Revolution Medicines Regeneron Pharmaceuticals Pfizer AstraZeneca Gilead Sciences Chongqing Precision Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.